Eli Lilly lowers insulin costs as coronavirus crisis deepens, as reported by Reuters on CNBC.com, 7 April 2020.
Drugmaker Eli Lilly said on Tuesday it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom are facing financial difficulties due to the coronavirus outbreak.
The new co-pay scheme covers most of Lilly’s insulins, including widely-used Humalog injection, and can be purchased by people with commercial insurance as well as those without insurance.
However, patients with government insurance such as Medicaid, Medicare, Medicare Part D or any State Patient or Pharmaceutical Assistance Program are not eligible for the scheme, Lilly said.
Read more: Eli Lilly lowers insulin costs as coronavirus crisis deepens
Abbott’s FreeStyle® Libre Now Available in U.S. for Hospitalized Patients with Diabetes During COVID-19 Pandemic, reported by PR Newswire on SeekingAlpha.com, 8 April 2020.
Abbott announced today that the FreeStyle Libre 14 day system, the world’s leading continuous glucose monitoring (CGM) technology, can now be used in the hospital setting during the COVID-19 pandemic, according to the U.S. Food and Drug Administration (FDA). This will permit frontline healthcare workers to remotely monitor patients with diabetes receiving inpatient care by assessing real-time glucose levels and glucose history. To help hospitals and medical centers in COVID-19 outbreak hotspots ramp up access to the technology, Abbott will donate 25,000 FreeStyle Libre 14 day sensors in partnership with the American Diabetes Association (ADA), Insulin for Life USA and Diabetes Disaster Response Coalition.
While I think this is remarkable, Libre still requires a medical professional to “swipe” over the transmitter … meaning another exposure to patients with Covid. WHY NOT DEXCOM??? Dexcom is TRULY REMOTE!
Read more: Abbott’s FreeStyle Libre System Now Available in U.S. for Hospitalized Patients with Diabetes
Senseonics Halts Sales of Eversense Implantable CGM was reported by Mike Hoskins and Amy Tenderich for DiabetesMine.com, 31 March 2020.
Senseonics, makers of Eversense, the first and only implantable continuous glucose monitor (CGM), announced on March 26 that the company would be “restructuring” and halting sales to new customers. This comes just 18 months after Eversense snagged approval from the Food and Drug Administration (FDA) and launched here in the United States.
As of March 27, the company has laid off about half of their workforce, retaining only researchers, quality control experts, and a few salespeople — while they search for new investors, partners, and/or a possible acquisition, according to Senseonics Chief Medical Officer Dr. Francine Kaufman.
“I guess you could say the company is now hibernating,” said Kaufman, who just took the leadership role at Senseonics in early 2019 after serving in a similar role at Medtronic Diabetes for a decade. “Our primary focus now will be R&D and maintenance of our commitments to those who were interested and innovative enough to try the system over the last 18 months.”
Existing customers currently using the Eversense CGM are promised they can continue getting supplies and support “for the foreseeable future.”
Read more and why: Senseonics Halts Sales of Eversense Implantable CGM
